Cue Biopharma (CUE) Return on Sales (2018 - 2025)

Cue Biopharma (CUE) posted Return on Sales of 0.0% for Q4 2025, up 105.43% sequentially from 0.04% in Q3 2025, and up 6.0% YoY from 0.0% in Q4 2024.

Cue Biopharma (CUE) Return on Sales (2018 - 2025) Analysis & Trends

Cue Biopharma has reported Return on Sales for 8 years, with the latest figure at 0.0% in Q4 2025.

Quarterly Return on Sales rose 6.0% year-over-year to 0.0% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.02% (up 3.0% YoY) and the FY2025 annual result came in at 0.01%, up 3.0% from the prior year.
Return on Sales improved to 0.0% in Q4 2025 per CUE's latest filing, from 0.04% in the prior quarter.
Over five years, Return on Sales peaked at 0.0% in Q4 2025 and troughed at 5.11% in Q2 2022.
A 5-year average of 0.49% and a median of 0.07% in 2023 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2023: Return on Sales tumbled 508 bps in 2022, then soared 502 bps in 2023.
Over 5 years, Return on Sales stood at 0.01% in 2021, then plunged by 10345 bps to 1.0% in 2022, then soared by 93 bps to 0.07% in 2023, then increased by 19 bps to 0.06% in 2024, then surged by 104 bps to 0.0% in 2025.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.04%, and 0.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Cue Biopharma	152.56 Mn	135.14 Mn	-	-0.11%

Download Data